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Abstract Angiogenesis plays an important role in cancer
progression in many types of cancer. Evaluation of angiogen-
esis is often performed, but the optimal methodology for
human cancer has not been agreed upon. As adequate evalu-
ation of angiogenesis in cancer tissues might be important for
prediction of prognosis and treatment decisions, we evaluated
angiogenesis semiquantitatively by assessing microvessel
density (MVD) in urothelial cancer of the upper urinary tract
(UC-UUT). We compared the performance of three endothe-
lial cell markers (CD31, CD34, and CD105) on formalin-fixed
tissues from 122 patients diagnosed with UC-UUT without
metastasis. Vascular endothelial growth factor (VEGF)-A ex-
pression was also evaluated immunohistochemically.
Correlations between MVD with each marker and pT stage,
grade, survival, and VEGF-A expression were investigated.
Mean (standard deviation) MVD as estimated by immunohis-
tochemical staining with anti-CD31, anti-CD34, and anti-
CD105 were 47.1 (17.9)/high-power field (HPF), 70.9
(19.5)/HPF, and 31.2 (16.7)/HPF, respectively. Although all
MVDs were significantly associated with pT stage and grade,
CD105-MVD showed the strongest association. Similarly,
CD105-MVD showed the strongest correlation with VEGF-
A expression (r =0.530, p <0.001). Although all MVDs were
associated with metastasis-free survival and cause-specific
survival on univariate analysis, only CD105-MVD was
retained as an independent predictor in multivariate analysis
including pT stage and grade. CD105-MVD may be the
preferredmarker for semiquantitative assessment of angiogen-
esis in patients with UC-UUT.
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Introduction
Angiogenesis is an important step for tumor growth and
progression in almost all malignancies [1]. Numerous inves-
tigations have focused on the pathological role, clinical sig-
nificance, and predictive value of angiogenesis in patients
with cancer. In human cancer tissues, the most representative
method for (semi-)quantification of angiogenesis is the mea-
surement of microvessel density (MVD) using endothelium-
specific markers. This approach is highly suitable for
histodiagnostic applications because it can be performed on
formalin-fixed and paraffin-embedded specimens. There is a
general agreement that MVD offers an important and useful
prognostic marker of tumor progression and survival in vari-
ous types of cancer.
Urothelial cancer (UC) frequently recurs and metastasizes
despite adequately performed surgery [2]. Many investigators
have investigated the pathological significance and prognostic
role of angiogenesis in patients with UC of the urinary bladder
and upper urinary tract (UUT), but conflicting results have
been published regarding the relationship between MVD and
malignant potential, clinicopathological features, and progno-
sis. Although some reports have described positive correla-
tions between MVD and malignant potential cancer cell
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progression and poor survival [3–5], others have shown no
significant relationship betweenMVD and tumor progression,
and others even considered MVD as a favorable predictor for
survival [6, 7]. Such contradictory results are most likely
attributable to the use of different markers for detecting endo-
thelial cells in different studies.
To detect neovascular microvessels, various markers have
been used for immunohistochemical staining of endothelial
cells. CD31, CD34, and CD105 have often been used on
human cancer tissues, including UC [8–14]. The biology of
these markers differs, and no single endothelial marker might
be perfect under all conditions. Studies comparing these
markers have been performed on different cancer types in
recent years [8–12].MVD assessment using CD105 asmarker
(CD105-MVD) has been proposed as a better predictor of
progression and prognosis than that using CD31 or CD34 in
a variety of cancers [8, 9, 12–14]. Several studies have inves-
tigated the clinical significance and pathological role of
CD105-MVD in bladder cancer patients [15, 16].
However, reports on the relationship between CD105-
MVD and clinicopathological features, tumor progression,
and survival in patients with UC-UUT have not been pub-
lished as yet.
The main aim of this study was to elucidate the role in
pathological assessment and clinical significance of CD105-
MVD in UC-UUT. We therefore evaluated CD105-MVD in
UC-UUT patients without metastasis and compared the results
with those for CD31-MVD and CD34-MVD. Furthermore,
we analyzed the correlations with expression of vascular
endothelial growth factor (VEGF)-A for CD31-MVD and
CD34-MVD.
Materials and methods
Patients and tissue samples
Specimens from 122 consecutive patients who had been di-
agnosed with non-metastatic UC-UUT were examined.
Patients who had received any preoperative therapy were
excluded. Specimens with carcinoma in situ were also exclud-
ed because MVDwas difficult to evaluate in some specimens.
All histological characteristics, including tumor grade and pT
stage, were determined using formalin-fixed paraffin-
embedded specimens from the resection specimen, and both
staging and grading were assessed using the 2002 tumor–node
metastasis classification. Cancer grade was divided into three
grades (i.e., G1, G2, and G3), according to the World Health
Organization classifications. A single pathologist performed
all pathological examinations. Median duration of follow-up
was 50 months (range, 2–250 months). The study protocol
was approved by the human ethics review committee of
Nagasaki University Hospital.
Immunohistochemistry and evaluation
Five-micrometer thick sections were deparaffinized step-
wise in xylene and rehydrated in graded solutions of
ethanol. Antigen retrieval was performed at 95 °C for
40 min in 0.01 M sodium citrate buffer (pH 6.0). All
sections were then immersed in 3 % hydrogen peroxide
for 30 min to block endogenous peroxidase activity.
Primary antibodies were obtained from Novocastra (New
Castle, UK; anti-human CD31 antibody), DakoCytomation
(Glostrup, Denmark; anti-human CD34 antibody), Vector
Laboratories (Burlingame, CA; anti-human CD105 antibody),
and Santa Cruz Biotechnology (Santa Cruz, CA; anti-VEGF-
A antibody). Sections were incubated overnight with primary
antibodies at 4 °C. After incubation with primary antibody,
sections were washed extensively and treated with peroxidase
using the labeled polymer method with Dako EnVisionTM
peroxidase (Dako, Carpinteria, CA) for 60 min. The peroxi-
dase reaction was visualized using a liquid DAB substrate kit
(Zymed Laboratories, San Francisco, CA). Sections were
counterstained with hematoxylin, dehydrated stepwise
through a graded alcohol series, and cleared in xylene
before mounting. Consecutive sections from each sam-
ple processed without the primary antibody were used
as negative control. Positive controls for all antibodies
comprised of kidney tissues including renal cell carci-
noma. Methods of immunohistochemical staining for all
antibodies except CD105 have been described previously
[4, 17, 18].
All analyses of immunohistochemically stained sections
were performed using light microscopy within the tumor area.
Expression levels of VEGF family members were assessed
semiquantitatively from the percentage of VEGF-expressing
carcinoma cells (from ≥500 carcinoma cells) using a method
similar to that described previously in detail [4, 17, 18].
Two investigators (S.W. and Y.M.) who were blinded to
clinical features and survival data independently performed
semiquantitative analyses and immunostaining interpreta-
tions. The disagreement rate for analyses between these two
investigators was less than 10 %, and results from both inves-
tigators were averaged for statistical analyses.
To determine the MVD, tumor sections stained with each
antibody were examined under a Nikon E-400 bright-field
microscope (Nikon, Tokyo, Japan), and images were captured
using a digital camera (DU100; Nikon) at ×200 objective lens
magnification. For each tumor section, 3–5 fields with the
greatest density of positively stained vessels (hot spots) were
evaluated, irrespective of the tumor region. MVDwas defined
as the number of positively stained vessels per high-power
field (HPF) estimated using computer-aided image anal-
ysis (WinROOF version 6.4; Mitani, Fukui, Japan). In
our system, the field area of 1 HPF corresponded to
0.392 mm2.
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Statistical analyses
Normality was evaluated by normal distribution and histo-
grams for each variable, and results are expressed as mean ±
standard deviation (SD) unless otherwise stated. Student’s t
test was performed for continuous variables. The Scheffé’s
test was used for multiple comparisons of data. Pearson’s
correlation was used to evaluate relationships between con-
tinuous variables and the correlation coefficient (r ).
Corresponding p values are shown. Spearman’s rank correla-
tion coefficient was calculated to confirm Pearson’s correla-
tion. In survival analyses, variables that achieved statistical
significance in univariate analyses were subsequently entered
into multivariate analysis using Cox proportional hazards
analysis. In this study, each MVD was measured as a contin-
uous variable.We therefore performed survival analyses using
two models as follows: MVD as a continuous variable (model
A), and MVD values less than or equal to the median versus
MVD values above the median (model B). All statistical tests
were two-sided, and significance was defined as p <0.050. All
statistical analyses were performed on a personal computer
using the StatView for Windows statistical package (version
5.0; Abacus Concepts, CA).
Results
The study population comprised of 92 men and 30 women,
with a median age at the time of surgery of 68 years (range,
39–87 years). The pathological features are shown in Table 1.
The most frequent pT stage was pT1 in 42 patients (34.7 %),
followed by pT3 in 34 patients (27.3 %). In our study popu-
lation, the number of patients with muscle invasion (68,
55.7 %) was higher than that without muscle invasion (54,
44.3 %). The most frequent grade in our study population was
high grade (G3) in 47 patients (38.5 %).
Representative examples of CD31-, CD34-, and CD105-
stained vessels in non-muscle-invasive cancer tissues are shown
in Fig. 1a–c, respectively. Representative examples of CD31-,
CD34-, and CD105-stained vessels in invasive tumor tissues are
shown in Fig. 1d–f. Mean n ± SD (median) CD31-, CD34-, and
CD105-MVDs were 47.1±17.9 (58.4)/HPF, 70.9±19.5 (69.0)/
HPF, and 31.2±16.7 (22.3)/HPF, respectively. CD34-MVDwas
significantly higher than the other values (p<0.001). On the
other hand, CD105-MVD was the lowest of the three.
Significant differences were apparent between MVDs in low
pT stage (non-muscle-invasive, pTa +1) and high (muscle-inva-
sive, pT 2–4) (p<0.001, Table 1). Similar results were also found
in the relationship between MVDs in low-grade (G1 + 2) and
high-grade (G3) tumors (Table 1). Detailed analysis of MVD
(Table 1) showed for CD31-MVD a significant difference be-
tween pTa and pT1 and between pT3 and pT4. For CD34-MVD,
a significant difference was only found between pT2 and pT3.
For CD105-MVD, a significant difference was found between
pTa and pT1, between pT1 and pT2, and between pT3 and pT4.
In addition, CD105-MVD was markedly lower in pTa than in
pT1, despite both representing non-muscle-invasive stages.
Similar analyses for grade (Table 1) showed that CD31-MVD
and CD34-MVD were significantly higher in G3 tumors than in
G2 tumors. However, no such significant difference was
detected between G1 and G2 tumors. In contrast, CD105-
MVD was closely associated with grade. With none of the
markers, striking differences in the location of “hot spots” for
MVD, as for example between the invasive front and tumor
center, were apparent.
Correlations between each MVD and VEGF-A expression
are shown in Fig. 2. In the whole cohort, all MVDs correlated
significantly with VEGF-A expression (Fig. 2a–c), but this
was strongest for CD105-MVD. In muscle-invasive disease,
similar results were found for all MVDs (Fig. 2c–e). However,
in non-muscle-invasive disease, CD105-MVD correlated with
VEGF-A expression (Fig. 2h), whereas no such difference
was found for CD31- or CD34-MVD (Fig. 2f, g).
We analyzed the prognostic value of each MVD for metas-
tasis after primary treatment (Table 2). Univariate analysis
showed that all MVDs significantly associated with metasta-
sis. However, CD31-MVD and CD34-MVD were not identi-
fied as independent significant predictors in a multivariate
analysis model including pT stage, grade, and adjuvant ther-
apy. For cause-specific survival, similar results were shown
for both uni- and multivariate analyses (Table 2). Models A
and B showed similar results in all survival analyses.
Discussion
In this study, we compared MVDs determined by immuno-
histochemical staining of vessels using three antibodies in
tissues from non-metastatic UC-UUT: anti-CD31, anti-
CD34, and anti-CD105. Our results show that staining with
anti-CD105 more accurately reflects pathological features
than that with the other antibodies and represents the most
useful predictor of outcome.
CD105, endoglin, is a cell membrane glycoprotein that
modulates angiogenesis by regulating cellular proliferation,
differentiation, and migration [19]. Several investigators have
reported preferential expression of CD105 in activated endo-
thelial cells participating in neoangiogenesis particularly in
cancer, with no or only weak expression in blood vessels of
most normal tissues [13, 14]. Several reports have positively
associated CD105-MVD with cancer cell invasion and metas-
tasis in malignancies including cervical and head and neck
cancers [20, 21]. In addition, increased CD105-MVD has
been associated with worse survival in several types of cancer,
including breast and head and neck cancer [13, 21]. Our
findings are in line with these reports. On the other hand,
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earlier reports regarding CD105-MVD and pTstage in bladder
cancer patients with non-muscle-invasive disease showed no
difference in CD105-MVD between pTa and pT1 tumors [15].
We have no explanation for these discrepancies, but the choice
of the antibody, method of unmasking, tissue characteristics,
and microvessel definition might be involved.
Table 1 Relationship between
each microvessel density (MVD)
and pathological features
MVD microvessel density, P p
value, G grade
N CD31-MVD CD34-MVD CD105-MVD
Mean (SD) p value Mean (SD) p value Mean (SD) p value
pT stage
Low 54 36.5 (8.6) <0.001 60.6 (13.7) <0.001 18.5 (7.7) <0.001
High 68 55.3 (19.0) 78.6 (19.6) 41.0 (14.6)
Ta 12 35.0 (9.0) 0.996 58.7 (12.8) 0.994 9.3 (3.8) 0.028
T1 42 37.0 (8.6) 0.093 61.2 (14.3) 0.860 20.5 (5.3) <0.001
T2 23 47.5 (16.6) 0.338 65.9 (14.0) 0.002 34.0 (12.7) 0.119
T3 34 55.8 (17.0) 0.042 84.0 (20.9) 0.793 42.0 (11.8) 0.010
T4 11 71.6 (20.4) 91.2 (8.9) 54.3 (16.1)
Grade
Low 75 41.9 (15.2) <0.001 65.7 (17.9) <0.001 24.4 (12.6) <0.001
High 47 55.5 (18.8) 79.3 (19.3) 41.2 (17.2)
G1 23 37.5 (9.4) 0.326 62.3 (12.3) 0.581 17.4 (7.6) 0.012
G2 52 43.8 (16.9) 0.003 67.2 (19.8) 0.006 28.0 (13.3) <0.001
G3 47 55.5 (18.8) 79.3 (19.3) 41.2. (17.2)
Fig. 1 a–c Representative tissues
from non-muscle-invasive
urothelial cancer of the upper
urinary tract with staining for
CD31 (a), CD34 (b), and CD105
(c). Some vessels stained strongly
for CD31 and CD34. However,
such strongly stained vessels were
relatively lower in CD105
compared to CD31 and CD34.
d–f Representative tissues from
muscle-invasive cancer with
staining for CD31 (d), CD34
(e), and CD105 (f). With regard
to staining intensity, CD34 was
clearly stained in both non-
muscle-invasive and muscle-
invasive disease. On the other
hand, CD105 clearly showed a
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Our results also show that CD31-MVD and CD34-MVD are
significantly higher in muscle-invasive than in non-muscle-
invasive disease and are associated with progression and surviv-
al in patients with UC-UUT. Similar findings have been de-
scribed in previous reports [3, 4]. We consider these MVDs to
still be useful for evaluating angiogenic status. MVD as mea-
sured using these antigens has been evaluated in several previ-
ous reports on human UC specimens, providing useful informa-
tion in terms of clinical significance of angiogenesis [4, 5, 15,
22]. However, our multivariate analyses show that CD31-MVD
and CD34-MVD are not independent significant predictors of
outcome.We propose that CD31-MVD andCD34-MVD do not
adequately reflect malignant potential and should be con-
sidered insufficient for predicting prognosis in patients
with non-metastatic UC-UUT.
CD31, a platelet endothelial cell adhesion molecule 1, is an
endothelial cell antigen. Anti-CD31 antibody stains macrophages
and plasma cells in paraffin-embedded specimens [23], but this
staining can be reduced by microwave antigen retrieval [24].
CD34, a transmembrane glycoprotein, is a hematopoietic progen-
itor cell antigen. Anti-CD34 antibodies stain endothelial cells in
neoplasia more strongly than normal endothelium, and constitute
a very sensitive marker of endothelial differentiation [25].
However, anti-CD34 antibodies also stain fibroblasts, adipocytes,
and lymphatic endothelial cells [26], which might interfere with
an MVD count, notably as regards lymphatic vessels. As a
consequence, in all earlier reports, MVD-CD34 was higher com-
pared to MVD-CD31 and/or MVD-CD105 [10, 12, 15]. Using
anti-CD31 and anti-CD105, staining intensity seems to be higher
in muscle-invasive than in non-muscle-invasive cancer but not
with anti-CD34, which supports the notion that anti-CD34 detects
various normal as well as cancer-related endothelial cells.
Various findings, thus, support the hypothesis that CD105-
MVD might reflect pathological and prognostic significance
Fig. 2 Correlations between VEGF expression and each type of
microvessel density (MVD) are shown. CD31-MVD (a–c) correlated
significantly with VEGF expression in the overall patient population
(a) and in patients with muscle-invasive disease (c), but not in patients
with non-muscle-invasive disease (b). Similar findings were found for
CD34-MVD (d–f). CD105-MVD correlated with all conditions, includ-
ing overall population (g), non-muscle-invasive disease (h), and muscle-
invasive disease (i)
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of angiogenesis more accurately than CD31-MVD or CD34-
MVD. In line with our findings on non-metastatic UC-UUT,
in breast, lung, and ovarian cancer, CD105-MVD associated
with worse prognosis [12–14], but CD34-MVD did not. This
is contested by other reports, e.g., in cervical cancer, with high
CD31-MVD predicting progression-free survival and overall
survival, whereas high CD105-MVD only showed a trend for
worse survival [11]. It is suggested that CD31-positive endo-
thelial cells are in more stable blood vessels, while CD105-
positive endothelial cells reflect newly formed leaky vessels,
less efficient in delivery of oxygen and nutrients, but provid-
ing a more efficient route of metastatic spread. Another report
showed that in multivariate analyses, CD34-MVD correlated
with survival for lung cancer, whereas CD105-MVD did not
[27]. Further detailed investigations are needed to establish
optimal conditions to evaluate MVD in cancer, including
marker and antibody choice, definition of microvessels and
blood vessels, and microscopy conditions.
Of note, all of our MVDs showed a positive correlation
with VEGF-A expression in the whole cohort (Fig. 2).
Interestingly, when analyzed separately in non-muscle-
invasive and muscle-invasive tumors, CD31- and CD34-
MVD correlated significantly with VEGF-A expression in
muscle-invasive but not in non-muscle-invasive disease,
whereas for CD105-MVD, this difference was not found.
We ruled out a pT stage bias as explanation. VEGF-A expres-
sion has been higher in high-stage UC than in low-stage UC
[22, 28]. There is a general agreement that VEGF-A expression
is closely associated with tumor-associated angiogenesis. We
speculate that CD31-MVD and CD34-MVD reflects angiogen-
ic status only in muscle-invasive disease when VEGF-A is
highly expressed. CD105-MVD might be more closely
associated with the proangiogenic functions of VEGF-A
in human UC-UUT tissues, as has been suggested for
other cancer types. For example, CD105-MVD closely
associated with VEGF-A expression in gastric cancer [29]
and hepatocellular carcinoma [9]. Furthermore, VEGF-A ex-
pression associated with CD105-MVD, but with neither
CD31-MVD in anaplastic astrocytoma nor CD34-MVD in
endometrial cancer [8, 30].
In conclusion, our results show that CD105-MVD is more
closely associated with malignant potential and tumor growth
than CD31-MVD or CD34-MVD. Only CD105-MVDwas an
independent predictor for tumor progression and survival on
multivariate analysis. Therefore, CD105 is the pan-endothelial
marker of choice for evaluating cancer-related angiogenesis in
UC-UUT.
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Table 2 Each microvessel densi-
ty (MVD) and outcome after pri-
mary treatment
Model A continuous variables of
MVD were used for analyses
Model B over median levels was
defined as risk
HR hazard ratio, CI confidential
interval, P p value, MVD
microvessel density, CSS
cause-specific survival
Univariate analysis Multivariate analysis
HR 95 % CI p value HR 95 % CI p value
For metastasis
(Model A)
CD31-MVD 1.044 1.024–1.064 <.0001 1.022 0.998–1.047 0.070
CD34-MVD 1.031 1.013–1.048 0.001 1.014 0.994–1.035 0.212
CD105-MVD 1.053 1.038–1.069 <0.001 1.031 1.002–1.061 0.038
(Model B)
CD31-MVD 3.71 1.65–8.36 0.016 1.47 0.59–3.69 0.409
CD34-MVD 2.59 1.21–5.54 0.015 1.06 0.43–2.57 0.911
CD105-MVD 10.56 3.67–30.41 <0.001 5.40 1.34–21.8 0.018
For CSS
(Model A)
CD31-MVD 1.042 1.020–1.063 <0.001 1.015 0.406–2.192 0.254
CD34-MVD 1.056 1.033–1.079 <0.001 1.016 0.993–1.040 0.167
CD105-MVD 1.034 1.015–1.055 0.001 1.032 1.001–1.064 0.041
(Model B)
CD31-MVD 2.39 1.04–5.12 0.040 0.94 0.41–2.19 0.828
CD34-MVD 2.54 1.12–5.73 0.025 0.93 0.36–2.38 0.875
CD105-MVD 12.89 3.84–43.27 <0.001 4.30 1.07–17.25 0.040
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